WO2013093508A3 - Wnt pathway inhibitors - Google Patents

Wnt pathway inhibitors Download PDF

Info

Publication number
WO2013093508A3
WO2013093508A3 PCT/GB2012/053248 GB2012053248W WO2013093508A3 WO 2013093508 A3 WO2013093508 A3 WO 2013093508A3 GB 2012053248 W GB2012053248 W GB 2012053248W WO 2013093508 A3 WO2013093508 A3 WO 2013093508A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
wnt pathway
methods
pathway inhibitors
cells
Prior art date
Application number
PCT/GB2012/053248
Other languages
French (fr)
Other versions
WO2013093508A2 (en
Inventor
Daniel Holsworth
Jo Waaler
Ondrej Machon
Stefan Krauss
Andrey Edward Voronkov
Original Assignee
Oslo University Hospital Hf
Golding, Louise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo University Hospital Hf, Golding, Louise filed Critical Oslo University Hospital Hf
Publication of WO2013093508A2 publication Critical patent/WO2013093508A2/en
Publication of WO2013093508A3 publication Critical patent/WO2013093508A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A class of compounds having general formula (I) has been identified. These compounds function as inhibitors of the Wnt pathway. Compounds of formula (I) are suitable for the treatment and/or prevention of any condition or disease in which it is desirable to inhibit signaling in the Wnt pathway, in particular inhibiting the proliferation of tumor cells, especially those associated with breast cancer, non-small cell lung cancer, pancreatic and colorectal cancers (e.g. colon carcinoma cells). The compounds also find use in methods of preventing metastasis and methods of promoting and/or directing cellular differentiation of progenitor cells.
PCT/GB2012/053248 2011-12-22 2012-12-21 Wnt pathway inhibitors WO2013093508A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579094P 2011-12-22 2011-12-22
US61/579,094 2011-12-22

Publications (2)

Publication Number Publication Date
WO2013093508A2 WO2013093508A2 (en) 2013-06-27
WO2013093508A3 true WO2013093508A3 (en) 2013-10-24

Family

ID=47557380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/053248 WO2013093508A2 (en) 2011-12-22 2012-12-21 Wnt pathway inhibitors

Country Status (1)

Country Link
WO (1) WO2013093508A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2686347T3 (en) 2011-03-16 2018-10-31 Argenx Bvba Antibodies to cd70
EP2976327B1 (en) 2013-03-20 2017-06-21 Bayer Pharma Aktiengesellschaft 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
JP2016521259A (en) 2013-03-20 2016-07-21 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted N-biphenyl-3-acetylamino-benzamide and N- [3- (acetylamino) phenyl] -biphenyl-carboxamide and their use as inhibitors of the Wnt signaling pathway
EP3119787A1 (en) * 2014-03-20 2017-01-25 Bayer Pharma Aktiengesellschaft Inhibitors of the wnt signalling pathways
AP2016009432A0 (en) * 2014-03-20 2016-09-30 Bayer Pharma AG Novel compounds
UY36060A (en) * 2014-04-02 2015-10-30 Bayer Pharma AG AZOL COMPOUNDS REPLACED WITH AMIDA
CN104974106B (en) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5- alkyl-[1,3,4]-oxadiazoles -2- alkyl formate synthetic method
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CN107531634A (en) 2015-02-20 2018-01-02 拜耳制药股份公司 The formamide of 3 Carbamoylphenyl 4 and isophtalamide derivative as WNT signal pathway inhibitors
JP2018507212A (en) 2015-02-20 2018-03-15 バイエル・ファルマ・アクティエンゲゼルシャフト N-phenyl- (morpholin-4-yl or piperazinyl) acetamide derivatives and their use as inhibitors of the WNT signaling pathway
JP2018505906A (en) 2015-02-20 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitors of Wnt signaling pathway
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
US20170210741A1 (en) * 2016-01-27 2017-07-27 Southern Research Institute Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
UY38511A (en) 2018-12-18 2020-07-31 Argenx Bvba COMBINATION THERAPY CD70
TW202334157A (en) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 Wnt pathway inhibitor compound

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025770A1 (en) * 1998-10-30 2000-05-11 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
WO2006136829A2 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
EP2058315A1 (en) * 2007-10-30 2009-05-13 Nerviano Medical Sciences S.r.l. 1H-Furo[3,2-C]Pyrazoles active as aurora kinase inhibitors
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms
US20090246137A1 (en) * 2008-03-31 2009-10-01 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
WO2009133294A2 (en) * 2008-04-09 2009-11-05 Centre National De La Recherche Scientifique Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
EP2377851A1 (en) * 2008-12-25 2011-10-19 Taisho Pharmaceutical Co., Ltd. Isoquinoline derivative
WO2012082817A1 (en) * 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025770A1 (en) * 1998-10-30 2000-05-11 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
WO2006136829A2 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
EP2058315A1 (en) * 2007-10-30 2009-05-13 Nerviano Medical Sciences S.r.l. 1H-Furo[3,2-C]Pyrazoles active as aurora kinase inhibitors
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms
US20090246137A1 (en) * 2008-03-31 2009-10-01 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
WO2009133294A2 (en) * 2008-04-09 2009-11-05 Centre National De La Recherche Scientifique Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
EP2377851A1 (en) * 2008-12-25 2011-10-19 Taisho Pharmaceutical Co., Ltd. Isoquinoline derivative
WO2012082817A1 (en) * 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GOLDFARB, DAVID SCOTT: "Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds", XP002696598, retrieved from STN Database accession no. 2009:846114 *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GOLDFARB, DAVID SCOTT: "Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds", XP002696599, retrieved from STN Database accession no. 2009:769551 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 July 2004 (2004-07-12), CHEMBRIDGE CORPORATION, XP002696607, retrieved from STN accession no. 708279-26-9 Database accession no. 708279-26-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 May 2004 (2004-05-13), CHEMBRIDGE CORPORATION, XP002696601, retrieved from STN accession no. 709000-49-7 Database accession no. 709000-49-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 September 2003 (2003-09-15), AMBINTER, XP002696606, retrieved from STN accession no. 585552-03-0 Database accession no. 585552-03-0 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2004 (2004-06-17), CHEMBRIDGE CORPORATION, XP002696600, retrieved from STN accession no. 694485-33-1 Database accession no. 694485-33-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2004 (2004-06-17), CHEMBRIDGE CORPORATION, XP002696604, retrieved from STN accession no. 694460-78-1 Database accession no. 694460-78-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 July 2004 (2004-07-20), CHEMBRIDGE CORPORATION, XP002696609, retrieved from STN accession no. 713097-75-7 Database accession no. 713097-75-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 June 2004 (2004-06-22), CHEMICAL BLOCK LTD., XP002696605, retrieved from STN accession no. 697232-52-3 Database accession no. 697232-52-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 29 August 2003 (2003-08-29), AMBINTER, XP002696602, retrieved from STN accession no. 575470-12-1 Database accession no. 575470-12-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 September 2003 (2003-09-03), AMBINTER, XP002696603, retrieved from STN accession no. 577988-68-2 Database accession no. 577988-68-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 September 2003 (2003-09-04), AMBINTER, XP002696608, retrieved from STN accession no. 578752-47-3 Database accession no. 578752-47-3 *
DEGRAW J I ET AL: "HISTAMINE RELEASERS. III. DIBASIC ACID AMIDES OF 4-PHENYL-4-AMINOMETHYLPIPERIDINES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 10, 1 March 1967 (1967-03-01), pages 174 - 177, XP001087644, ISSN: 0022-2623, DOI: 10.1021/JM00314A010 *
JENNA L. RIFFELL ET AL: "Tankyrase-targeted therapeutics: expanding opportunities in the PARP family", NATURE REVIEWS DRUG DISCOVERY, vol. 11, no. 12, 30 November 2012 (2012-11-30), pages 923 - 936, XP055062120, ISSN: 1474-1776, DOI: 10.1038/nrd3868 *
RADIA OUELAA-BENSLAMA ET AL: "Pinworm and TNKS inhibitors, an eccentric duo to derail the oncogenic WNT pathway", CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol. 35, no. 8-9, 1 September 2011 (2011-09-01), pages 534 - 538, XP055062119, ISSN: 2210-7401, DOI: 10.1016/j.clinre.2011.03.015 *
SHIH-MIN A. HUANG ET AL: "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling", NATURE, vol. 461, no. 7264, 16 September 2009 (2009-09-16), pages 614 - 620, XP055062115, ISSN: 0028-0836, DOI: 10.1038/nature08356 *
WAALER JO ET AL: "A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 72, no. 11, 1 June 2012 (2012-06-01), pages 2822 - 2832, XP008161857, ISSN: 0008-5472, [retrieved on 20120322], DOI: 10.1158/0008-5472.CAN-11-3336 *

Also Published As

Publication number Publication date
WO2013093508A2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
WO2013093508A3 (en) Wnt pathway inhibitors
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MX360404B (en) Compounds for inhibiting cell proliferation in egfr-driven cancers.
MX2015007205A (en) Histone demethylase inhibitors.
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2010141738A3 (en) Compositions and method for inhibiting tumor growth
WO2013063560A3 (en) INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
MX2015005772A (en) Substituted tricyclic benzimidazoles as kinase inhibitors.
IN2015DN00827A (en)
MX366804B (en) R-spondin translocations and methods using the same.
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
EA201391114A1 (en) METHODS OF USE ALK-INHIBITORS
MX357502B (en) Pyrrolotriazinone derivatives.
EA201790502A1 (en) HYSTON DIMETHYLASE INHIBITORS
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
NZ627480A (en) Inhibitors of iap
MX336761B (en) Compounds for treatment of cancer.
MX2014008864A (en) Triazolo[4,5-d]pyrimidine derivatives.
CR20110479A (en) PHARMACEUTICAL COMBINATIONS UNDERSTANDING RDEA 119 / BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS
MX2010005324A (en) Compositions and methods for inhibiting tumor progression.
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
WO2013169771A3 (en) Methods and compositions for the prognosis and treatment of relapsed leukemia
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
WO2012166463A3 (en) Aminooxazole inhibitors of cyclin dependent kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12813945

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12813945

Country of ref document: EP

Kind code of ref document: A2